Literature DB >> 15167072

Uncertainties in the pathogenesis of adult dermatomyositis.

Steven A Greenberg1, Anthony A Amato.   

Abstract

PURPOSE OF REVIEW: Dermatomyositis is an inflammatory disorder of muscle affecting both children and adults. The pathogenesis of adult dermatomyositis is reviewed here, with particular attention to gaps and uncertainties in our current understanding of this disease, in order to focus attention on the outstanding research questions with regard to disease mechanisms. RECENT
FINDINGS: The conceptual model of the pathophysiology of dermatomyositis has been based on work extending back over at least 35 years, with important findings related to the deposition of membrane attack complex, the character of the inflammatory infiltrate, and the primacy of capillary abnormalities established over 10 years ago. The lack of significant additions to the understanding of this disease over the past few years suggests a state of contentment with current knowledge. Accordingly, we emphasize the uncertainties of this knowledge and the need for re-addressing some of its basic tenets.
SUMMARY: Although evidence remains strong that dermatomyositis is a disorder with an early involvement of the capillaries, the concept that it results from an antibody-mediated attack upon the endothelium is uncertain. It is not clear whether membrane attack complex is activated by antibody-dependent or independent means, whether or not intramuscular B cells are antigen specific and synthesize significant quantities of antibodies, whether the presence of tubuloreticular inclusions precedes, follows, or is independent of membrane attack complex deposition, what is the mechanism of perifascicular atrophy, and what is the relationship of dermatomyositis to systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15167072     DOI: 10.1097/00019052-200406000-00018

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  16 in total

1.  Rituximab: a review of dermatological applications.

Authors:  Jason J Emer; Wolinsky Claire
Journal:  J Clin Aesthet Dermatol       Date:  2009-05

2.  Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.

Authors:  Ronan J Walsh; Sek Won Kong; Yihong Yao; Bahija Jallal; Peter A Kiener; Jack L Pinkus; Alan H Beggs; Anthony A Amato; Steven A Greenberg
Journal:  Arthritis Rheum       Date:  2007-11

Review 3.  Dermatomyositis.

Authors:  M S Krathen; D Fiorentino; V P Werth
Journal:  Curr Dir Autoimmun       Date:  2008

4.  Contrast-enhanced ultrasound in dermatomyositis- and polymyositis.

Authors:  Marc-André Weber; Uta Jappe; Marco Essig; Martin Krix; Carina Ittrich; Hagen B Huttner; B Hagen Huttner; Uta Meyding-Lamadé; Marius Hartmann; Hans-Ulrich Kauczor; Stefan Delorme
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

Review 5.  Dermatomyositis and type 1 interferons.

Authors:  Steven A Greenberg
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

Review 6.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Authors:  Angela Ceribelli; Maria De Santis; Natasa Isailovic; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 7.  [Myositides].

Authors:  A Bornemann; S Heitmann; A Lindner
Journal:  Pathologe       Date:  2009-09       Impact factor: 1.011

Review 8.  Advances in the immunopathophysiology of the idiopathic inflammatory myopathies: not as simple as suspected.

Authors:  Gerald J D Hengstman
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

9.  Treatment of Susac's Syndrome.

Authors:  Robert M Rennebohm; Robert A Egan; John O Susac
Journal:  Curr Treat Options Neurol       Date:  2008-01       Impact factor: 3.598

10.  Clinical presentation and evaluation of dermatomyositis.

Authors:  Umaima Marvi; Lorinda Chung; David F Fiorentino
Journal:  Indian J Dermatol       Date:  2012-09       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.